Chemed Q4 2023 Adj EPS $6.60 Beats $6.25 Estimate, Sales $585.91M Miss $586.64M Estimate
Portfolio Pulse from Benzinga Newsdesk
Chemed (NYSE:CHE) reported Q4 2023 adjusted EPS of $6.60, surpassing the $6.25 estimate, but its sales of $585.91M slightly missed the $586.64M estimate. This represents a 7.18% increase in sales compared to the same period last year.
February 27, 2024 | 10:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chemed reported a Q4 2023 adjusted EPS of $6.60, beating estimates, but sales of $585.91M slightly missed expectations. Year-over-year sales increased by 7.18%.
The positive earnings surprise, with adjusted EPS beating estimates by 5.6%, is likely to be viewed favorably by investors, potentially leading to a short-term uptick in CHE's stock price. However, the slight miss on sales estimates could temper some of the positive sentiment. The year-over-year sales growth of 7.18% indicates a strong underlying business performance, further supporting a positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100